Evotec SE (EVT.DE)
| Previous Close | 9.69 |
| Open | 9.61 |
| Bid | 9.56 x 105300 |
| Ask | 9.56 x 169300 |
| Day's Range | 9.54 - 9.70 |
| 52 Week Range | 8.52 - 24.44 |
| Volume | |
| Avg. Volume | 1,466,648 |
| Market Cap | 1.69B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.47 |
| Earnings Date | May 22, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
ACCESSWIREEvotec SE to Announce Results for First Quarter 2024 on 22 May 2024
HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024. The Company is going ...
GlobeNewswireCENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-dr
- ACCESSWIRE
Bayer and Evotec Collaborate to Advance Precision Cardiology
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES ...
